Plexxikon, Roche to work together on new class of cancer drugs

10/9/2006 | American City Business Journals

Roche will pay up to $700 million to Calif.-based biotech Plexxikon to create a new early-stage cancer therapy based on the biotech's compound, which attracted a lot of attention. The drug selectively inhibits a genetic mutation, called B-RafV600E kinase, found in more than 70% of malignant melanomas and a large percentage of other cancers and tumor types.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC